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Ropinirole In The Treatment Of Motor Deficits After Stroke: A Randomized, 
Placebo-Controlled, Double-Blind Study. 
Steven C Cramer, Univ of California, Irvine, Orange, CA; Bruce H Dobkin, UCLA, L.A., CA; 
Elizabeth A Noser, Univ of Texas, Houston, Houston, TX; Rachelle W Rodriguez, Univ of 
Calttornia, Irvine, Orange, CA; Lori A Enney; GlaxoSmithKline, Rsch Triangle Park, NC 
INTRODUCTION: Several studies suggest the potential to improve motor status in patients with 
stroke by modifying the function of brain catecholamine receptors. Dopamine receptors are an 
attractive target given the importance of this neurotransmitter to a multitude of processes 
including attention, learning, motivation, and motor function. The current study hypothesized 
that a 9-week course of the dopamine agonist Ropinirole plus physical therapy (PT) would be 
a safe and effective way to increase gait velocity. METHODS: Entry criteria included stroke 
1-12 mo prior, no depression (HAM-D score < 17), moderate motor deficits (arm/leg
Fugl-Meyer score 23-83/100), and 50 foot walk > 15 sec. Patients were randomized
(double-blinded, stratified for time post-stroke) to 9 weeks of Ropinirole (ROP) or placebo
(PLAC), with doses (0.25mg - 4mg QD) titrated weekly as tolerated. All subjects received 8 PT 
sessions focused on gait, leg, and arm, in weeks 5-9. Assessments extended to week 12, i.e.,
3 weeks after drug washout. The primary endpoint, gait velocity, was analyzed using repeated
measures ANOVA to examine differences in treatment groups over the 9 weeks of therapy.
RESULTS: At 3 U.S. sites, 744 patients were screened and 33 enrolled (age 61 +/- 14 yr; time
post-stroke, 30 +/- 15 wks; mean +/- SD). Of these, 16 were randomized to PLAC+PT and
17 to ROP+ PT (mean final daily ROP dose, 2.6 mg). Across all patients, significant gains were
found over time for the primary endpoint, gait velocity at week 9 (p=0.0001), and for most 
secondary endpoints, with gains still significant at week 12. However, gains did not differ by
treatment assignment (time X group interaction non-significant), for example: gait velocity 
increase from baseline to week 9 went from 0.54 +/- 0.37 to 0.72 +/- 0.46 (ROP+PT) vs. 
from 0.49 +/- 0.28 to 0.69 +/- 0.40 (PLAC+PT, p=0.88); and SIS-16, from 56 +/- 10 to 66 
+/- 9 vs. from 58 +/- 11 to 65 +/- 9 (p=0.72). None of the 5 serious adverse events was 
attributable to drug effects. Outside therapy during the study was common, e.g., 61 % patients 
received outside PT (mean 12 sessions). Of patients who received ROP, 93% accurately 
guessed treatment assignment. Results of serial functional MRI testing will be presented. 
CONCLUSIONS: PT improves motor function in patients with chronic stroke. PT was also 
commonly prescribed as standard of care outside of study-related interventions. At the doses 
achieved in this trial, ROP was safe but did not show any improvement over and above the 
favorable effects of PT. CLINICALTRIALS.GOV IDENTIFIER: NCT00221390 
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